文献速递胸部肿瘤

CROWN研究7年更新:洛拉替尼一线治疗ALK阳性NSCLC

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.
PubMed 文献 · Ann Oncol · 2026-05-29

CROWN III期研究7年随访显示,洛拉替尼一线治疗晚期ALK阳性NSCLC的中位无进展生存期(PFS)仍未达到,而克唑替尼为9.1个月(HR 0.19),7年PFS率分别为55%和3%。洛拉替尼组24个月无进展患者7年无进展生存概率为79%,且30个月后无新发颅内进展事件,安全性与此前一致。

要点

  • 洛拉替尼一线治疗7年PFS率55%,克唑替尼仅3%,HR 0.19。
  • 洛拉替尼组24个月无进展者7年无进展生存概率79%。
  • 洛拉替尼30个月后无新发颅内进展,颅内进展风险HR 0.06。

核心结论

  • CROWN研究7年随访中洛拉替尼组中位PFS仍未达到,持续显示前所未有的长期获益。
  • 洛拉替尼一线治疗可能使晚期ALK阳性NSCLC向慢性病演变。

研究设计与样本

  • III期CROWN研究事后分析,纳入296例未经治疗的晚期ALK阳性NSCLC患者。
  • 患者1:1随机接受洛拉替尼100mg每日一次(n=149)或克唑替尼250mg每日两次(n=147)。

主要发现

  • 洛拉替尼中位随访83.0个月,克唑替尼77.2个月;洛拉替尼中位PFS未达到(95%CI 68.5-NR),克唑替尼9.1个月(95%CI 7.4-10.9),HR 0.19(95%CI 0.13-0.26)。
  • 7年PFS率洛拉替尼55%,克唑替尼3%。
  • 洛拉替尼组24个月无PFS事件者7年无进展生存概率79%;洛拉替尼治疗30个月后无新发颅内进展事件。
  • 颅内进展中位时间洛拉替尼未达到(95%CI NR-NR),克唑替尼16.4个月(95%CI 12.7-21.9),HR 0.06(95%CI 0.03-0.12)。
  • 总生存随访仍在进行,未达到方案预设分析所需事件数;安全性与此前5年结果一致,洛拉替尼治疗26个月后无因治疗相关不良事件停药。

临床怎么用

  • 洛拉替尼可作为晚期ALK阳性NSCLC一线优选方案,尤其关注长期疾病控制。
  • 洛拉替尼治疗24个月无进展者7年进展或死亡风险低,可考虑继续长期治疗。

局限性

  • 总生存数据尚未成熟,未达到方案预设分析所需事件数。
  • 本研究为事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Due to the unprecedented progression-free survival (PFS) benefit with lorlatinib after 5 years of follow-up in the phase III CROWN study, we aimed to quantify long-term outcomes at 7 years. PATIENTS AND METHODS: Treatment-naive patients (N = 296) with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) were randomly assigned 1:1 to receive lorlatinib 100 mg once a day (n = 149) or crizotinib 250 mg twice a day (n = 147). This post hoc analysis presents investigator-assessed efficacy outcomes, safety, and biomarker analyses. RESULTS: With a median follow-up of 83.0 and 77.2 months, median PFS was not reached (NR) with lorlatinib [95% confidence interval (CI), 68.5-NR] and was 9.1 months (95% CI 7.4-10.9) with crizotinib [hazard ratio (HR) 0.19, 95% CI 0.13-0.26]; 7-year PFS was 55% and 3%, respectively. With lorlatinib, patients without a PFS event at the end of 24 months had a 79% probability of survival without progression at year 7. No new intracranial progression events occurred after the first 30 months on lorlatinib. Median time to intracranial progression was NR (95% CI NR-NR) with lorlatinib and 16.4 months (95% CI 12.7-21.9) with crizotinib (HR 0.06, 95% CI 0.03-0.12). Overall survival follow-up is ongoing; the number of events for a protocol-specified analysis has not been met. The safety profile was consistent with the 5-year results. With lorlatinib, treatment-related adverse events did not lead to discontinuations after the first 26 months. More genetic alterations were detected in circulating tumor DNA samples from early progressors than in long-term responders on lorlatinib; new potential resistance mechanisms were identified. CONCLUSIONS: With median PFS yet to be reached after 7 years of follow-up in CROWN, lorlatinib continues to show unprecedented long-term benefit in patients with advanced ALK-positive NSCLC. Patients without progression within 24 months on lorlatinib have a low risk of progression or death at year 7 and may continue long-term treatment. Findings suggest that sustained long-term disease control with first-line lorlatinib may enable advanced ALK-positive NSCLC to evolve toward a chronic condition.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Shaw AT, Solomon BJ, Felip E, et al. Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study. Ann Oncol. 2026. PMID: 42217582. doi:10.1016/j.annonc.2026.05.692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。